You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    AbstractProject Summary Cognition Therapeutics IncsCogrxmission is to develop effective therapeutics for Alzheimer s diseaseADOligomers of the brain protein Amyloid betaA Oshave been identified as toxic components that are involved with disease progressionCognition has identified a subset of sigmareceptor binding modulators that displaces A Os from synaptic receptor sites and clears them into the ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Automated Object Contouring Methods and Software for Radiotherapy Planning

    SBC: Quantitative Radiology Solutions LLC            Topic: 102

    Abstract In 2015, 1,658,370 new cancer cases are estimated to occur in the US, where nearly two-thirds will have radiation therapy (RT). Given that there are over 2,300 RT centers in the US, and current systems for contouring organs at risk (OARs) rely mostly on manual methods, there is a strong commercial opportunity for producing a software system that can contour OARs in medical images at a hig ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation

    SBC: LIPELLA PHARMACEUTICALS INC.            Topic: 300

    ABSTRACT This Phase II SBIR proposal leverages the progress made in Phase I on the development of a novel contrast mixture enhanced Tweighted MRI technique as a safesensitiveand objective diagnostic test for the increased permeability in the luminal surface of the urinary bladder in Interstitial Cystitis Bladder Pain SyndromeIC BPSpatientsThe purpose of having such a test is ultimately to allow cl ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Innovative Mitigation of Radiation Effects in Advanced Technology Nodes

    SBC: MICROELECTRONICS RESEARCH DEVELOPMENT CORPORATION            Topic: DTRA16A003

    Micro-RDC has developed portable radiation effects test structures that scale to new process nodes.These structures will enable the investigation of the effects of radiation on the new technology from the material processing level as well as the circuit level.Fabricating the chosen structures and the refinement of software to extract the model parameters will be completed in this effort.A suite of ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  7. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    The ultimate goal of this Phase I application is to develop novel small moleculebroad spectrum therapeutics against viral infections caused by filoviruses that depend on the PPxY L domain motif for virus egress and spread of infectionEbolaEBOVand MarburgMARVviruses are highly pathogenic and classified as Category Ahigh priority bioterror pathogensAs there are no commercially available therapeutic ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate

    SBC: NeuroKine Therapeutics, LLC            Topic: NIA

    ABSTRACT Alzheimer s diseaseADand related dementias are increasing rapidly yetremarkablythere are no approved disease modifying drugsVirtually all trials targeting amyloid related pathways have failed over the lastyearsRegrettablyfew alternative targets or pathways have been exploredThereforethere is an urgent need to explore alternative pathways as monotherapies or as constituents of a multi drug ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government